Observational, multicentre study to evaluate the effectiveness in routine clinical practice of Lanreotide Autogel 120 mg at extended dosing intervals (>4 weeks) for the treatment of acromegaly: SOMACROL study

Cristina Álvarez Escolá1, Carmen Fajardo2, Mónica Marazuela3, Fernando Cordido Carballido4, Eva María Venegas5, Pedro de Pablos Velasco6, Gonzalo Piedrola Maroto7, Ma del Pilar Olvera Márquez8, Isabel Pavón de Paz1, Davi de Carvalho9, Carme Romero10, Guillermo De la Cruz11 & Ignacio Bernabéu12

1Hospital Universitario La Paz, Madrid, Spain; 2Hospital Universitario de La Ribera, Valencia, Spain; 3Hospital Universitario La Princesa, Madrid, Spain; 4Hospital Universitario A Coruña, A Coruña, Spain; 5Hospital Universitario Virgen del Rocío, Sevilla, Spain; 6Private Consultation, Las Palmas, Spain; 7Private Consultation, Granada, Spain; 8Hospital Universitario De Candelaria, Santa Cruz de Tenerife, Spain; 9Centro Hospitalar São João, Porto, Portugal; 10Adkoma Health Research S.L., Barcelona, Spain; 11IPSEN PHARMA, Barcelona, Spain; 12Hospital Clínico Universitario Santiago de Compostela, Santiago de Compostela, Spain.

Background: Acromegaly is usually caused by a benign pituitary tumour, with increased production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Treatment options include surgery, followed by pharmacological treatment with dopamine agonists, somatostatin analogues, GH receptor antagonists or radiotherapy. Treatment optimization is important to decrease the burden of this often-chronic disease on the patient.

Objectives: To evaluate the effectiveness in IGF-1 control of Lanreotide Autogel (LAN) 120 mg at extended dosing intervals (EDIs) (>4 weeks) in patients with acromegaly in routine clinical practice.

Methods: Observational, retrospective study at 38 sites (36 Spanish, 2 Portuguese) (NCT02807233). Targeted enrolment was 100 adult patients diagnosed with acromegaly, receiving LAN 120 mg at EDIs for ≥6 months, with available data on treatment start/schedule and blood GH and IGF-1 assay immediately before study visit, and no radiation therapy in the 6 months preceding. The primary outcome was the percentage of patients with normalized IGF-1 level after at least 6 months of LAN treatment at prolonged doses. Secondary outcomes included percentages of patients with GH levels ≤2.5 ng/ml or ≤1 ng/ml, and treated with EDIs of 5, 6, 7 or 8 weeks. Treatment satisfaction, quality of life (QoL) and treatment compliance were assessed.

Results: Of 114 patients included, 109 were evaluable. Mean (±S.D.) age was 59.1 (±13.2) years. 69.7% had tumour resection performed on average 12.8 (±9.4) years ago. 25.7% received radiotherapy on average 17.9 (±9.4) years ago. 83.5% had comorbidities, with hypertension the most common (64.4%). 77.1% had concomitant medication for conditions besides acromegaly. LAN had been the first-line pharmacological treatment for 67.0% of the patients. 91.7% had normalized IGF-1 values. 80.6% had GH levels ≤2.5 ng/ml, and 58.3% had levels ≤1 ng/ml. The EDIs most commonly used in routine clinical practice were 8 weeks (35.8%) and 6 weeks (37.6%). AcroQoL questionnaire showed that patients had a medium level of physical [59.7 (±24.5)] and psychological [64.9 (±20.1)] QoL. TQ10M-9 questionnaire revealed that patients were satisfied with treatment [75.1 (±16.6)], and considered it effective [70.6 (±18.7)] and convenient [69.1 (±17.6)]. General therapeutic compliance during preceding 6 months was 94.5%.

Conclusions: LAN 120 mg at EDIs (>4 weeks) during at least 6 months provided IGF-1 control in more than 90% of patients with acromegaly, with good levels of treatment satisfaction and compliance.

Acknowledgments: Sponsored by Ipsen.